Rebecca E. Wrishko
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Antifungal resistance and susceptibility, Lipoproteins and Cardiovascular Health, Anesthesia and Sedative Agents, Antibiotics Pharmacokinetics and Efficacy
Most-Cited Works
- → Tadalafil pharmacokinetics in healthy subjects(2005)282 cited
- → Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects(2008)116 cited
- → Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38(2009)83 cited
- → Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease(2009)73 cited
- → On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers(2015)71 cited
- → CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD(2007)67 cited
- → Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics(2006)67 cited
- → Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil(2009)63 cited
- → Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy(2011)55 cited
- → Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease(2008)52 cited